During the first year of the Rise to Immunize™ (RIZE) campaign, participants administered or documented more than five million vaccinations to their patients! Your hard work is helping protect more adult patients from vaccine-preventable diseases—congratulations to all RIZE groups! Some big-picture takeaways from year one:

- Your performance on the influenza measure had the greatest impact on progress toward our campaign goal. In just the first year, 3,799,935 influenza vaccines were administered or documented.
- The average pneumococcal vaccination rate remained steady between the previous baseline year and year one of the campaign at 77%, representing 182,872 vaccines administered or documented. Implementation of the new CDC guidelines will be a great opportunity to see real-time growth in this measure over the next three years.
- The Td/Tdap measure had the greatest variation in vaccination rates among organizations, ranging from 19% to 81%. We look forward to sharing lessons learned from top performers in this measure to help fellow participants drive improvement. A total of 586,153 Td/Tdap vaccines were administered or documented.
- The zoster measure saw great improvement in the first year, with the average rate increasing by 5% compared to the previous year. A total of 510,022 zoster vaccines were administered or documented. As organizations continue to increase administration and documentation of the new recombinant vaccine, we’re hopeful this measure will see sustained growth throughout the campaign.
- The average bundle measure rate was 15% in the first year. This was a 2% increase from last year’s rate of 13%. The increase in rate translates to approximately 53,000 more patients age ≥66 receiving more comprehensive immunization care this year.

We look forward to continuing to measure progress toward the campaign goal and sharing your successes! Join us during our Nov. 17 webinar when we will review the first year of data in more detail and hear from three award-winning groups that experienced impressive data achievements during year one.

As always, if you have any questions, please don’t hesitate to contact RiseToImmunize@amga.org.

Best,
- The RIZE Team

---

**Webinar Preview**

"Reducing Flu Vaccine Disparities"

The October campaign webinar will feature Leon Jerrels, MHA, MBA, RN, CPHQ from Kelsey-Seybold Clinic and Laura Lee Hall, PhD from the National Minority Quality Forum (NMQF). Mr. Jerrels is the director of quality improvement at Kelsey-Seybold Clinic and is a part of NMQF’s Health Champions program. He serves on the AMGA Foundation Board of Directors and as a National Advisor for the RIZE campaign. Dr. Hall is founder and president of NMQF’s Center for Sustainable Health Care Quality and Equity (SHC). Under Dr. Hall’s leadership, SHC has launched a variety of national health initiatives to reduce disparities and improve health equity—including efforts around flu vaccinations.

Join us on Oct. 20 to learn more from Mr. Jerrels and Dr. Hall about reducing flu vaccine disparities.
Upcoming Dates

Oct. 14 – Deadline to submit quarterly data (Learn more)

Oct. 20 – Monthly campaign webinar: “Reducing Flu Vaccine Disparities” at 2 p.m. ET (Register)

Nov. 17 – Monthly campaign webinar: “Year 1 Data Review & RIZE Awards” at 2 p.m. ET (Register)

Dec. 6 – Bonus webinar: “Vaccine Equity: Putting Strategies into Practice” at 2 p.m. ET (Register)

Campagne Spotlight

This month we spotlight all RIZE groups who participated in RIZE Action Month during August – thank you! 28 groups hosted events at their organizations and discussed the importance of providing strong vaccine recommendations. Among those organizations was Premier Medical Associates, P.C. (PMA), who was featured in the National Foundation for Infectious Diseases (NFID) Blog for their RIZE Action Month event. Read their blog post and learn more about what PMA has done to prepare for the upcoming vaccination season.

Thank you to PMA and all RIZE groups who participated in this annual observance—we appreciate your commitment to improving adult vaccination rates!

Resource of the Month

The CDC recently released an MMWR on seasonal influenza vaccines: “Prevention and control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices.” The report includes information on ACIP’s updates to the recommendations concerning vaccination of adults aged >65 years. ACIP recommends that adults age >65 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (allIV4). You can review the MMWR and the updated recommendation on the CDC’s website.